Breaking News Instant updates and real-time market news.

ACRX

AcelRx

$4.30

0.15 (3.61%)

, EW

Edwards Lifesciences

$140.16

-8.145 (-5.49%)

08:45
10/25/18
10/25
08:45
10/25/18
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: AcelRx (ACRX) 59.67% +0.93, Edwards Lifesciences (EW) 0.38% +0.12, ProShares Ultra (BOIL) 10.49% +0.07, Occidental Petroleum (OXY) 0.41% +0.06, iShares South Korea (EWY) 0.32% +0.04, Alerian (AMLP) 4.88% +0.03, Health Care Sector SPDR ETF (XLV) 0.51% +0.03, Turtle Beach (HEAR) 71.59% +0.03, Papa John's (PZZA) 2.09% +0.02, and Anheuser Busch (BUD) 1.34% +0.02.

ACRX

AcelRx

$4.30

0.15 (3.61%)

EW

Edwards Lifesciences

$140.16

-8.145 (-5.49%)

OXY

Occidental Petroleum

$68.16

-2.46 (-3.48%)

EWY

iShares MSCI South Korea Index Fund

$58.42

-2.06 (-3.41%)

XLV

Health Care Select Sector SPDR

$87.34

-2.66 (-2.96%)

HEAR

Turtle Beach

$17.49

-2.26 (-11.44%)

PZZA

Papa John's

$51.90

-0.1 (-0.19%)

BUD

AB InBev

$82.24

-1.71 (-2.04%)

  • 25

    Oct

  • 28

    Oct

  • 03

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 27

    Nov

ACRX AcelRx
$4.30

0.15 (3.61%)

10/15/18
CANT
10/15/18
NO CHANGE
Target $8
CANT
Overweight
AcelRx price target raised to $8 from $6 at Cantor Fitzgerald
Cantor Fitzgerald analyst Brandon Folkes raised his price target for AcelRx to $8 citing increased conviction that Dsuvia will be approved by the FDA on its November 3 action date following Friday's positive panel vote. AcelRx could have two product approvals within the next 12 months, along with the potential to launch or partner Dsuvia in Europe after approval earlier this year, Folkes tells investors in a research note. He believes upward earnings revisions will drive upside momentum in the stock and reiterates an Overweight rating on the name.
10/15/18
HCWC
10/15/18
NO CHANGE
Target $8
HCWC
Buy
H.C. Wainwright sees Dsuvia approval coming, raises AcelRx price target to $8
After AcelRx presented data from an enhanced application to an FDA expert panel one year after announcing a CRL on the original application for Dsuvia, H.C. Wainwright analyst Ed Arce now sees the drug being poised for approval following the panel's positive 10-3 vote. Ahead of what he sees as a Dsuvia launch in the first quarter of 2019, Arce raised his price target on AcelRx shares to $8 from $7 and keeps a Buy rating on the stock.
10/22/18
RBCM
10/22/18
NO CHANGE
Target $7
RBCM
Outperform
AcelRx price target raised to $7 from $5 at RBC Capital
RBC Capital analyst Randall Stanicky raised his price target on AcelRx to $7 and kept his Outperform rating. The analyst notes that the stock price has pulled back about 20% from the highs seen after the October 12th FDA advisory committee opinion for DSUVIA, and sees an "attractive" set-up going into its expected PDUFA approval on November 3rd. Stanicky cites future catalyst opportunities coming from a potential partnering deal in the EU for DZUVEO and an NDA resubmission of Zalviso coming up in about 6 months.
10/23/18
RILY
10/23/18
INITIATION
Target $9
RILY
Buy
AcelRx initiated with a Buy at B. Riley FBR
B. Riley FBR analyst David Buck started AcelRx Pharmaceuticals with a Buy rating and $9 price target. The company is nearing approval for its acute pain product candidates, Buck tells investors in a research note.
EW Edwards Lifesciences
$140.16

-8.145 (-5.49%)

10/24/18
WBLR
10/24/18
NO CHANGE
WBLR
Outperform
Edwards Lifesciences selloff brings 'compelling' opportunity, says William Blair
William Blair analyst Margaret Kaczor says the recent selloff in shares of Edwards Lifesciences provides a "compelling buying opportunity." While the Q3 results were a bit lower than expected, its fundamentals are intact and its growth should accelerate in 2019 with products launches and a "low-risk" approval, Kaczor tells investors in a research note. The analyst keeps an Outperform rating on Edwards Lifesciences.
10/24/18
JEFF
10/24/18
NO CHANGE
Target $168
JEFF
Buy
Jefferies sees 'nothing too worrying' in Edwards Lifesciences results
Jefferies analyst Raj Denhoy sees "puts and takes" in Edwards Lifesciences' Q3 earnings report. Transcatheter heart valve therapies sales guidance was cut to 12.5% from 15% on lower Cardioband sales, but underlying THVT results of up 12.7% were same as last quarter and Europe market share was stable, Denhoy tells investors in a research note titled "Nothing Too Worrying in 3Q; Have To Be There for 2019." He believes 2019 is "setting up as a banner year" for Edwards with low risk approval, Pascal approval in Europe, and Centera/Ultra pointing to accelerating growth despite new competition. The analyst recommends "staying the course" and keeps a Buy rating on the shares with a $168 price target.
10/24/18
LEHM
10/24/18
NO CHANGE
Target $143
LEHM
Underweight
Edwards Lifesciences shares should not be bought on weakness, says Barclays
Barclays analyst Kristen Stewart tells investors not to buy shares of Edwards Lifesciences on today's post-earnings weakness. Edwards reported Q3 sales that fell short of consensus expectations, mainly due to lighter transcatheter heart valve therapies sales, and tempered its THVT expectations for the remainder of the year, Stewart writes in a post-earnings research note. She says nothing in the quarter changed her view on the stock. The analyst keeps an Underweight rating on Edwards Lifesciences with a $143 price target.
10/16/18
10/16/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Abbott (ABT), Boston Scientific (BSX), Stryker (SYK), and Medtronic (MDT) were initiated with an Overweight at Barclays, while Baxter (BAX), Edwards Lifesciences (EW), and Zimmer Biomet (ZBH) were initiated with an Underweight. 2. Expedia (EXPE) was initiated with an Outperform at Evercore ISI, while TripAdvisor (TRIP) was initiated with an In Line, and Booking Holdings (BKNG) was initiated with an In Line. 3. Facebook (FB) was initiated with a Buy at Loop Capital and Rosenblatt. 4. Snap (SNAP) initiated with a Hold at Loop Capital. 5. VF Corp. (VFC) initiated with a Neutral at Wedbush. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
OXY Occidental Petroleum
$68.16

-2.46 (-3.48%)

09/27/18
PIPR
09/27/18
INITIATION
PIPR
Overweight
Occidental Petroleum assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Ryan Todd assumed coverage of Occidental Petroleum with an Overweight rating and a $90 price target.
10/15/18
MUFG
10/15/18
NO CHANGE
Target $92
MUFG
Neutral
Occidental Petroleum price target lowered to $92 from $97 at MUFG
MUFG analyst Michael McAllister lowered his price target on Occidental Petroleum to $92 and kept his Neutral rating after the company disclosed that it will stop operating the Idd El-Shargi field. The analyst also lowers his 2020 total production estimate by 2.5% to 768K MBOE per day to reflect the loss, even though Occidental Petroleum believes that it can make up the lost output by allocating the field's capital to other programs in its portfolio. Shares of Occidental Petroleum were down over 6% today on the news.
10/22/18
RAJA
10/22/18
UPGRADE
RAJA
Strong Buy
Occidental Petroleum upgraded to Strong Buy from Outperform at Raymond James
10/22/18
10/22/18
UPGRADE
Target $90

Strong Buy
Occidental Petroleum upgraded to Strong Buy on valuation at Raymond James
As previously reported, Raymond James upgraded Occidental Petroleum to Strong Buy from Outperform with a $90 price target. Analyst Pavel Molchanov said Occidental shares are down 2% year-to-date versus the E&P index's 8% gain, and the dividend yield now stands at 4.3%. The analyst believes this is an opportunistic time to upgrade shares given the firm's newly increased oil forecast.
EWY iShares MSCI South Korea Index Fund
$58.42

-2.06 (-3.41%)

XLV Health Care Select Sector SPDR
$87.34

-2.66 (-2.96%)

HEAR Turtle Beach
$17.49

-2.26 (-11.44%)

10/16/18
DADA
10/16/18
NO CHANGE
Target $58
DADA
Buy
DA Davidson recommends that investors buy Logitech ahead of earnings
DA Davidson analyst Tom Forte kept his Buy rating and $58 price target on Logitech ahead of its Q3 results next Monday, saying that he sees "multiple favorable data points indicating the continued strength of gaming accessories". The analyst recommends that investors purchase shares going into the company's earnings, as "recent data and comments from GameStop (GME), NPD, and Turtle Beach (HEAR) suggest continued robust demand for Fortnite gameplay "fueling further growth in headsets".
09/19/18
LSCM
09/19/18
NO CHANGE
Target $40
LSCM
Buy
Turtle Beach 45% pullback a buying opportunity, says Lake Street
Recent concerns over new Battle Royale introductions from the Call of Duty and Battlefield franchises impacting Fortnite/PUBG, and in turn accessory sales, are overblown and counterintuitive, Lake Street analyst Mark Argento tells investors in a research note. More game players equals more hardware sales, which means more headset sales, Argento contends. The analyst points out that Turtle Beach is game title agnostic. He views the August NPD video games sales data as strong and keeps a Buy rating on Turtle Beach with a $40 price target. Argento recommends using the recent 45% selloff in the shares as a buying opportunity.
10/11/18
LSCM
10/11/18
NO CHANGE
Target $40
LSCM
Buy
Lake Street reiterates $40 target on Turtle Beach after preannounced Q3 upside
Lake Street analyst Mark Argento reiterates a Buy rating on Turtle Beach with a $40 price target after the company announced preliminary Q3 results "significantly ahead" of both his and consensus estimates. The rise of the Battle Royale genre continues to drive increased demand for gaming headsets, Argento tells investors in a research note. Turtle Beach stated it will increase fiscal 2018 guidance by at least as much as the Q3 beat, which gives the analyst confidence that the company isn't pulling revenues from Q4 to drive the beat. He believes upside to Q4 numbers could "significantly exceed" his estimates as the "underlying trends remain strong." With the stock down 42% from its highs, Turtle Beach's earnings power is misunderstood, contends Argento. He would be buyer of the stock. Turtle Beach in morning trading is up $1.31 to $18.51
10/12/18
DADA
10/12/18
NO CHANGE
Target $38
DADA
Buy
Turtle Beach valuation now 'especially attractive', says DA Davidson
DA Davidson analyst Tom Forte kept his Buy rating and $38 price target on Turtle Beach (HEAR), saying the current valuation on the stock at 12.9-times free cash flow yield based on his expected 2020 forecasts makes the shares "especially attractive". The analyst notes that the company's Q3 pre-announcement affirmed his view of Turtle Beach being "incredibly well positioned to leverage the continued success of the battle royale gaming format", while commentary from Epic Games, NPD, and GameStop (GME) has also indicated that Fortnite demand remains very strong.
PZZA Papa John's
$51.90

-0.1 (-0.19%)

10/10/18
BTIG
10/10/18
NO CHANGE
Target $102
BTIG
Buy
Yum! Brands price target raised to $102 from $92 at BTIG
BTIG analyst Peter Saleh raised his price target on Yum! Brands (YUM) to $102 and kept his Buy rating, citing his greater confidence in the company's unit growth trends and potential for driving same-store sales gains. In the short run, the analyst points to the benefits coming from its Pizza Hut business and its partnership with the NFL, its new advertising campaign, and the potential market share gains from sales declines at Papa John's (PZZA). Longer term, Saleh sees "stronger international unit growth after the closing of the Telepizza master franchise deal "which should drive unit growth closer to 4.0%", along with benefits coming from all of Yum's segments' partnership with GrubHub (GRUB).
10/11/18
STFL
10/11/18
NO CHANGE
Target $48
STFL
Hold
Papa John's price target raised to $48 at Stifel on higher odds of deal
Stifel analyst Chris O'Cull said he has a "conflicted" view on Papa John's because fundamentals remain poor, but this has likely motivated the board to move quickly to take advantage of a "white-hot restaurant M&A market." While stating he has "no knowledge of a potential M&A transaction," O'Cull believes a strategic acquirer seems more likely than financial sponsor given the latter would be difficult due to the level of equity investment required. O'Cull keeps a Hold rating on Papa John's shares, but raised his price target to $48 from $38 to reflect what he sees as a higher probability of a deal occurring.
10/15/18
LBOW
10/15/18
NO CHANGE
LBOW
Buy
Papa John's U.S. comps began to recover in mid-September, says Longbow
Longbow analyst Alton Stump believes, based on his talks with Papa John's franchisees, that U.S. same-store sales began to recover in mid-September and to-date in October, which could drive upside for both its earnings and the stock's multiple. Same-store sales, which were down 11.5%-12% in August, recovered to a 9%-9.5% decline in September and a 7.5%-8% decline in October to-date, Stump estimates. He keeps a Buy rating on Papa John's shares.
10/10/18
MAXM
10/10/18
NO CHANGE
Target $305
MAXM
Hold
Domino's Pizza price target raised to $305 from $285 at Maxim
Maxim analyst Stephen Anderson raised his price target on Domino's Pizza (DPZ) to $305 after its investor meeting with the management last week, saying the company is "building a global fortress" and remains "unfazed" by competition. The analyst says Domino's Pizza should sustain its "best in class" performance in spite of the woes experienced by Papa John's (PZZA) and Pizza Hut (YUM) as it seeks more operational efficiencies on a "global scale" even though it may take a few quarters for cost savings to materialize. Anderson keeps his Hold rating on the shares, awaiting a deeper pullback before considering a more bullish stance.
BUD AB InBev
$82.24

-1.71 (-2.04%)

10/02/18
10/02/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. GE UPGRADED AT RBC, WOLFE: RBC Capital analyst Deane Dray upgraded General Electric (GE) to Outperform from Sector Perform and raised his price target for the shares to $15 from $13. The analyst believes a floor has been put in the shares following news of Larry Culp being named Chairman and CEO. Additionally, GE was upgraded to Outperform from Peer Perform at Wolfe Research. DEUTSCHE SEES HEIGHTENED RISKS TO FACEBOOK ESTIMATES: After attending the first day of AdWeek, Deutsche Bank analyst Lloyd Walmsley sees heightened risk to the Q3, Q4 and 2019 consensus estimates for Facebook (FB). The analyst said he's starting to hear more cautious feedback and that Facebook seems on the defensive, particularly following last week's data breach disclosure. Walmsley, however, continues to view Facebook as attractively valued and kept a Buy rating on the shares with a $205 price target. JPMORGAN ADDS WEIGHT WATCHERS TO FOCUS LIST: JPMorgan analyst Christina Brathwaite added Weight Watchers (WTW) to her firm's America's Analyst Focus while keeping an Overweight rating on the shares with a $120 price target. The stock's 30% pullback from its peak on June 20 presents a "compelling entry point for investors who missed the stock's appreciation the first time around," Brathwaite said. Despite the post-earnings selloff, the analyst believes the Q2 print was actually indicative that Weight Watchers' growth story remains on track. Further, she believes the changes announced last week, including its new rewards program, as well as the company's Invite a Friend program, will help drive member recruitment and retention going forward. AMBEV DOUBLE DOWNGRADED BY UBS: UBS analyst Alan Alanis double downgraded Ambev (ABEV) to Sell from Buy and lowered his price target for the shares to R$17 from R$23. AmBev trades at a 25% higher valuation than parent company AB InBev (BUD), which is unwarranted, Alanis believes. He believes Ambev shares at current levels are more than pricing in the company's favorable outlook. Further, he expects consensus estimates to come down due to a tougher competitive environment, a "tepid" Brazilian economic recovery and currency headwinds. DEUTSCHE DOWNGRADES METAL STOCKS: Deutsche Bank analyst Jeremy Kliewer downgraded Century Aluminum to Hold from Buy and lowered his price target for the shares to $15 from $20, stating that Century's margins could remain pressured for longer due to alumina supply disruptions. Meanwhile, Deutsche's Chris Terry downgraded Reliance Steel (RS) to Hold from Buy and lowered his price target for the shares to $90 from $100, and downgraded U.S. Steel (X) to Hold from Buy and lowered his price target for the shares to $35 from $47. The analyst said his view on the steel sector is "moderating post peak pricing." Most positive data points and catalysts have now largely played out, Terry believes.
10/02/18
UBSW
10/02/18
DOWNGRADE
UBSW
Sell
Ambev downgraded to Sell from Buy at UBS
UBS analyst Alan Alanis double downgraded Ambev (ABEV) to Sell from Buy and lowered his price target for the shares to R$17 from R$23. AmBev trades at a 25% higher valuation than parent company AB InBev (BUD), which is unwarranted, Alanis tells investors in a research note. He believes Ambev shares at current levels are more than pricing in the company's favorable outlook. Further, he expects consensus estimates to come down due to a tougher competitive environment, a "tepid" Brazilian economic recovery and currency headwinds.
10/01/18
JEFF
10/01/18
DOWNGRADE
JEFF
Hold
AB InBev downgraded to Hold from Buy at Jefferies
Jefferies analyst Edward Mundy downgraded AB InBev to Hold and lowered his price target for the shares to EUR 80 from EUR 100. The company's external environment could be challenged as volatility in emerging markets puts pressure on earnings and input costs, Mundy tells investors in a research note. He sees a lack of positive catalysts for AB InBev shares.
09/14/18
GUGG
09/14/18
INITIATION
Target $107
GUGG
Buy
AB InBev initiated with a Buy at Guggenheim
Guggenheim analyst Laurent Grandet initiated AB InBev with a Buy and $107 price target saying shares are undervalued relative to peers and believes concerns regarding US softness, Brazil volatility, and slower deleveraging are overdone.

TODAY'S FREE FLY STORIES

PINS

Pinterest

$26.69

0.68 (2.61%)

08:37
05/18/19
05/18
08:37
05/18/19
08:37
Periodicals
Pinterest committed 'cardinal sin' for newly public company, Barron's says »

Pinterest released its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSHB

KushCo Holdings

$0.00

(0.00%)

08:32
05/18/19
05/18
08:32
05/18/19
08:32
Periodicals
Pot paraphernalia companies taking hit from tariffs, Barron's says »

The U.S.-China trade…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

JWN

Nordstrom

$37.09

0.16 (0.43%)

08:24
05/18/19
05/18
08:24
05/18/19
08:24
Periodicals
Nordstrom stock a 'can't miss bargain.' Barron's says »

Nordstrom remains the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 23

    May

NTDOY

Nintendo

$0.00

(0.00%)

, TTWO

Take-Two

$106.76

-0.81 (-0.75%)

08:10
05/18/19
05/18
08:10
05/18/19
08:10
Periodicals
Take-Two 'winning the game,' Barron's says »

Videogame stocks are down…

NTDOY

Nintendo

$0.00

(0.00%)

TTWO

Take-Two

$106.76

-0.81 (-0.75%)

DIS

Disney

$135.04

-0.46 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

  • 06

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 12

    Jun

  • 24

    Jun

  • 13

    Nov

TPR

Tapestry

$30.78

-0.56 (-1.79%)

, REGN

Regeneron

$304.81

-4.69 (-1.52%)

08:01
05/18/19
05/18
08:01
05/18/19
08:01
Periodicals
Regeneron, Tapestry among cheap stocks to ride out trade war, Barron's says »

Applied Materials (AMAT),…

TPR

Tapestry

$30.78

-0.56 (-1.79%)

REGN

Regeneron

$304.81

-4.69 (-1.52%)

SCHW

Charles Schwab

$43.21

-0.94 (-2.13%)

BWA

BorgWarner

$36.27

-0.375 (-1.02%)

AMAT

Applied Materials

$42.72

-1.56 (-3.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 29

    May

  • 31

    May

  • 06

    Jun

  • 14

    Jun

  • 26

    Jun

  • 25

    Jul

MT

ArcelorMittal

$16.37

-0.485 (-2.88%)

, CLF

Cleveland-Cliffs

$10.02

-0.08 (-0.79%)

07:25
05/18/19
05/18
07:25
05/18/19
07:25
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

MT

ArcelorMittal

$16.37

-0.485 (-2.88%)

CLF

Cleveland-Cliffs

$10.02

-0.08 (-0.79%)

SCHN

Schnitzer Steel

$23.16

0.42 (1.85%)

BRSS

Global Brass and Copper

$43.09

-0.01 (-0.02%)

LXFR

Luxfer

$25.41

-0.44 (-1.70%)

MTRN

Materion

$66.36

0.155 (0.23%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$14.84

-0.01 (-0.07%)

F

Ford

$10.29

-0.1 (-0.96%)

GM

General Motors

$37.00

-0.36 (-0.96%)

HMC

Honda

$25.64

-0.135 (-0.52%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$118.40

-1.44 (-1.20%)

VWAGY

Volkswagen

$0.00

(0.00%)

SHOO

Steven Madden

$31.49

-0.37 (-1.16%)

GIII

G-III Apparel

$31.82

-0.35 (-1.09%)

IIVI

II-VI

$32.66

-1.64 (-4.78%)

LITE

Lumentum

$46.30

-4.15 (-8.23%)

MU

Micron

$36.06

-1.37 (-3.66%)

WDC

Western Digital

$44.62

-0.82 (-1.80%)

COHR

Coherent

$121.28

-5.22 (-4.13%)

LASR

nLight

$21.21

-1.27 (-5.65%)

VECO

Veeco

$12.50

-0.25 (-1.96%)

NPTN

NeoPhotonics

$3.83

-0.7 (-15.45%)

AAPL

Apple

$188.97

-0.93 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 24

    May

  • 28

    May

  • 29

    May

  • 03

    Jun

  • 04

    Jun

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 07

    Jun

  • 10

    Jun

  • 13

    Jun

  • 14

    Jun

  • 09

    Jul

  • 24

    Jul

  • 31

    Jul

  • 01

    Aug

  • 23

    Oct

WMT

Walmart

$100.88

-0.56 (-0.55%)

17:59
05/17/19
05/17
17:59
05/17/19
17:59
Hot Stocks
Walmart EVP Furner sells 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

  • 05

    Jun

  • 07

    Jun

  • 07

    Jun

  • 15

    Aug

  • 13

    Nov

XOM

Exxon Mobil

$75.91

-0.44 (-0.58%)

, REPYY

Repsol

$0.00

(0.00%)

17:56
05/17/19
05/17
17:56
05/17/19
17:56
Periodicals
Exxon Gulf of Mexico sale gets interest from Repsol, Ineos, Bloomberg says »

Exxon Mobil (XOM) has…

XOM

Exxon Mobil

$75.91

-0.44 (-0.58%)

REPYY

Repsol

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 29

    May

IEF

iShares 7-10 Year Treasury Bond ETF

$106.74

0.04 (0.04%)

, SHY

iShares 1-3 Year Treasury Bond

$84.15

0.02 (0.02%)

17:43
05/17/19
05/17
17:43
05/17/19
17:43
General news
Weekly CFTC Commitment of Traders highlights »

2-YEAR U.S. TREASURY net…

IEF

iShares 7-10 Year Treasury Bond ETF

$106.74

0.04 (0.04%)

SHY

iShares 1-3 Year Treasury Bond

$84.15

0.02 (0.02%)

SPY

SPDR S&P 500 ETF Trust

$285.98

-1.87 (-0.65%)

SLV

iShares Silver Trust

$13.52

-0.14 (-1.02%)

GLD

SPDR Gold Shares

$120.64

-0.86 (-0.71%)

FXE

Euro Currency Trust

$106.35

-0.13 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$285.98

-1.87 (-0.65%)

17:39
05/17/19
05/17
17:39
05/17/19
17:39
Periodicals
IMF's Lagarde: U.S.-China trade spat may be risk to global economy, Reuters says »

IMF managing director…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$285.98

-1.87 (-0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIG

Hartford Financial

$53.58

-0.02 (-0.04%)

17:34
05/17/19
05/17
17:34
05/17/19
17:34
Syndicate
Breaking Syndicate news story on Hartford Financial »

Hartford Financial files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

AFH

Atlas Financial

$0.91

0.0225 (2.53%)

17:33
05/17/19
05/17
17:33
05/17/19
17:33
Hot Stocks
Atlas Financial receives filing delinquency notice from Nasdaq »

Atlas Financial received…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WES

Western Gas Partners

$30.60

-0.155 (-0.50%)

17:29
05/17/19
05/17
17:29
05/17/19
17:29
Syndicate
Breaking Syndicate news story on Western Gas Partners »

Western Gas Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$354.99

0.5 (0.14%)

17:24
05/17/19
05/17
17:24
05/17/19
17:24
Hot Stocks
Boeing awarded $163.91M Navy contract modification »

Boeing has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

LMT

Lockheed Martin

$338.10

-2.39 (-0.70%)

17:18
05/17/19
05/17
17:18
05/17/19
17:18
Hot Stocks
Lockheed Martin subsidiary awarded $1.13B Navy contract modification »

Sikorsky, a Lockheed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

COTY

Coty

$13.50

0.25 (1.89%)

17:14
05/17/19
05/17
17:14
05/17/19
17:14
Hot Stocks
Coty exec Pieraccioni acquires 93,100 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMR

Alta Mesa Resources

$0.18

-0.0027 (-1.50%)

17:14
05/17/19
05/17
17:14
05/17/19
17:14
Hot Stocks
Alta Mesa Resources receives noncompliance notification from Nasdaq »

Nasdaq notified Alta Mesa…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NJR

New Jersey Resources

$49.82

-0.03 (-0.06%)

17:06
05/17/19
05/17
17:06
05/17/19
17:06
Hot Stocks
New Jersey Resources' Trice sells 12,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

AHC

A.H. Belo

$3.82

-0.075 (-1.93%)

17:03
05/17/19
05/17
17:03
05/17/19
17:03
Hot Stocks
A.H. Belo sells former Dallas Morning News campus for $31.6M »

A. H. Belo announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRA

Telaria

$8.56

0.2 (2.39%)

17:01
05/17/19
05/17
17:01
05/17/19
17:01
Hot Stocks
Telaria director Rossman sells 173K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 10

    Jun

HL

Hecla Mining

$1.53

0.015 (0.99%)

16:58
05/17/19
05/17
16:58
05/17/19
16:58
Syndicate
Breaking Syndicate news story on Hecla Mining »

Hecla Mining files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INNT

Innovate Biopharmaceuticals

$1.59

-0.095 (-5.65%)

16:57
05/17/19
05/17
16:57
05/17/19
16:57
Syndicate
Breaking Syndicate news story on Innovate Biopharmaceuticals »

Innovate files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 31

    May

JONE

Jones Energy

$0.00

(0.00%)

16:56
05/17/19
05/17
16:56
05/17/19
16:56
Hot Stocks
Jones Energy emerges from bankruptcy »

Jones Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPP

Hudson Pacific

$34.33

-0.15 (-0.44%)

16:44
05/17/19
05/17
16:44
05/17/19
16:44
Hot Stocks
Hudson Pacific CFO sells ~57K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

GLYC

GlycoMimetics

$12.42

-0.43 (-3.35%)

16:36
05/17/19
05/17
16:36
05/17/19
16:36
Syndicate
Breaking Syndicate news story on GlycoMimetics »

GlycoMimetics files $250M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.